Aura Biosciences, Inc. (AURA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $914.77M; Treasury Stock, Common, ValueUSD $39.09M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-670.00K.
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD $621.56M; Treasury Stock, Common, ValueUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-207.00K.
- 2025-12-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD $617.43M; Treasury Stock, Common, ValueUSD $0.00; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-102.00K.
- 2025-09-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD $611.46M; Treasury Stock, Common, ValueUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $69.00K.
Aura Biosciences, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $914.77M | $39.09M | $-670.00K | $-559.74M | $315.27M | 6.92M | 3 month · $12.37M | (m) |
| 2026-03-31 | (m) | $621.56M | (m) | $-207.00K | $-514.10M | $107.25M | (m) | 3 month · $3.82M | (m) |
| 2025-12-31 | (m) | $617.43M | $0.00 | $-102.00K | $-480.42M | $136.91M | 0.00 | 12 month · $14.32M | (m) |
| 2025-09-30 | (m) | $611.46M | (m) | $69.00K | $-454.86M | $156.67M | (m) | 3 month · $3.69M | (m) |
| 2025-06-30 | (m) | $603.33M | (m) | $25.00K | $-428.73M | $174.63M | (m) | 3 month · $3.83M | (m) |
| 2025-03-31 | (m) | $529.57M | (m) | $105.00K | $-401.71M | $127.97M | (m) | 3 month · $3.51M | 3 month · $27.00K |
| 2024-12-31 | (m) | $525.93M | (m) | $263.00K | $-374.23M | $151.97M | (m) | 12 month · $11.72M | (m) |
| 2024-09-30 | (m) | $522.45M | (m) | $607.00K | $-348.39M | $174.67M | (m) | 3 month · $2.75M | (m) |
| 2024-06-30 | (m) | $518.99M | (m) | $-183.00K | $-327.35M | $191.45M | (m) | 3 month · $3.13M | (m) |
| 2024-03-31 | (m) | $515.78M | (m) | $18.00K | $-307.01M | $208.78M | (m) | 3 month · $2.91M | (m) |
| 2023-12-31 | (m) | $512.62M | (m) | $539.00K | $-287.31M | $225.85M | (m) | 12 month · $8.77M | (m) |
| 2023-09-30 | (m) | $417.03M | (m) | $-134.00K | $-265.18M | $151.72M | (m) | 3 month · $2.33M | (m) |
| 2023-06-30 | (m) | $413.32M | (m) | $-223.00K | $-246.66M | $166.44M | (m) | 3 month · $1.93M | (m) |
| 2023-03-31 | (m) | $408.67M | (m) | $-45.00K | $-228.37M | $180.26M | (m) | 3 month · $1.91M | (m) |
| 2022-12-31 | (m) | $406.56M | (m) | $-72.00K | $-210.90M | $195.58M | (m) | 12 month · $6.41M | 12 month · $62.00K |
| 2022-09-30 | (m) | $309.54M | (m) | $-147.00K | $-194.34M | $115.05M | (m) | 3 month · $1.72M | 3 month · $62.00K |
| 2022-06-30 | (m) | $307.66M | (m) | $-128.00K | $-178.44M | $129.09M | (m) | 3 month · $1.29M | (m) |
| 2022-03-31 | (m) | $306.06M | (m) | $-5.00K | $-164.97M | $141.09M | (m) | 3 month · $1.59M | (m) |
| 2021-12-31 | (m) | $304.45M | (m) | (m) | $-152.14M | $152.31M | (m) | 12 month · $2.31M | (m) |
| 2021-09-30 | (m) | $9.49M | (m) | (m) | $-140.50M | $-131.01M | (m) | 3 month · $554.00K | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $-122.75M | (m) | 3 month · $271.00K | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $-114.19M | (m) | 3 month · $185.00K | (m) |
| 2020-12-31 | (m) | $8.17M | (m) | (m) | $-116.89M | $-108.71M | (m) | 12 month · $736.00K | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-104.00M | (m) | 3 month · $191.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-100.58M | (m) | 3 month · $189.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-94.71M | (m) | 3 month · $177.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-87.41M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |